Background: Cystic fibrosis (CF) is a genetic disorder that afflicts over 70,000 people worldwide. It is characterized by viscous mucus that accumulates in the lungs creating challenges for microbiology labs processing sputa toisolates lower growing fungal species. Our laboratory attempted to liquefy and homogenize mucoid sputum samples by exposure to Adaptive Focused Acoustics™ (AFA) in order to increase recovery of fungal pathogens.
Woburn, MA – September 1st, 2015 – truXTRAC is a comprehensive novel solution for clinical-grade DNA extraction from Formalin-Fixed, Paraffin-Embedded (FFPE) tissues utilizing Covaris Adaptive Focused Acoustics® (AFA™) technology. The unique focused, short-wavelength acoustic field generated by AFA enables rapid, active paraffin removal and rehydration of FFPE tissue samples in aqueous buffer, thus enabling efficient and rapid tissue digestion, crosslink reversal, and nucleic acid release.
Covaris, Inc., an innovator in the life science tools and the clinical diagnostic market spaces, announced today that its European subsidiary, Covaris Ltd, which is located in the United Kingdom, will commence
operations on May 1, 2014.
Read More: Press Release FFPE HTP Feb 12 2014
Covaris featured in recent Health Heroes episode broadcast on Fox Business News and Discovery Channel.
Woburn, MA, — Covaris, Inc., the leader in focused acoustic technologies for the life sciences, is pleased to announce the establishment of a marketing alliance with HORIBA Instruments of Irvine, CA, which is the U.S. sales and marketing division of HORIBA Limited of Kyoto, Japan. This alliance integrates the Covaris Adaptive Focused Acoustics (AFA) and the HORIBA particle sizing technologies into the world’s first fully automated formulation preparation station with integrated Process Analytical Technology (PAT).
Under the arrangement, the Covaris FS-220 GMP system will be integrated with HORIBA’s LA-950V2 platform, providing point-of-use particle size characterization. This PAT system is ideal for formulation preparation from early animal studies through First-In-Human (FIH) testing. With full 21 CFR Part 11 compliant software, the combined system offers a complete solution in cGLP/cGMP environments.
Carl Beckett, General Manager of Covaris Process Technologies, states that, “We are enthusiastic about this association. This combined system will accelerate drug development by improving the quality of studies up to and including FIH testing. Also, it reduces errors when handing off preparations between the Discovery and Development Research centers and the Contract Research Organizations (CRO) by allowing a completely automated and documented method development. Additionally, as our clients scale to FIH and ultimately clinical processes, they need to ensure the methods in development are phase appropriate and based on scalable technologies.”
According to Dr. Mike Pohl, Vice President of HORIBA’s Scientific Division, “Our client base ranges from startups to the largest multinational Pharma and Biotech companies. As a result of our entering into this relationship with Covaris, our clients gain access to the most advanced technology. It’s critical that the analytic and characterization capabilities keep pace with the formulation technology, through the entire discovery/development cycle.” Dr. Pohl notes that many pharmaceutical customers are located along the East Coast. “The combination of our Edison, NJ headquarters plus theWoburn,MAlocation of Covaris, Inc.; gives HORIBA a strong one-two punch to support these customers. The ability to automate the preparation of formulations, and then document the quality up front prior to a study, will now be readily accessible to our customers.”
The HORIBA Group of worldwide companies provides an extensive array of instruments and systems for applications ranging from automotive R&D, process and environmental monitoring, in-vitro medical diagnostics, semiconductor manufacturing and metrology, to a broad range of scientific R&D and QC measurements. Proven quality and trustworthy performance have established widespread confidence in the HORIBA Brand.
Covaris Process Technologies designs, develops, and markets systems based on patented Adaptive Focused Acoustic (AFA) technology. The AFA process, based on shock wave physics, delivers controlled, precise, and accurate energy to biological and chemical samples. The process is non-contact, isothermal, and rapid. Leading pharmaceutical companies worldwide are using Covaris instruments for Formulation development, of nanosuspensions, liposomes, and nanoemulsions.
Information about Covaris Process Technologies is available at http://www.covarisinc.com
Information about HORIBA Scientific is available at http://www.horiba.com/scientific
Carl Beckett, General Manager, Covaris Process Technologies, 14 Gill St Unit H, Woburn MA 01801, 781-932-3959 ext. 231, firstname.lastname@example.org
Carol Madden, Marketing Specialist, HORIBA Instruments Inc., 34 Bunsen, Irvine California 92618, 800-446-7422 ext. 1133, email@example.com.
Woburn Massachusetts, USA and São Paulo Brazil
Covaris Inc., has appointed Uniscience do Brasil as its authorized distributor in Brazil. Uniscience will supply the Brazilian LifeScience,drug discovery and development markets with Covaris sample-preparation products including, AFA Focused-ultrasonicators and consumables, as well as application specific reagent kits for NGS, ChIP, Proteomics, and Pharmaceutical applications.
“We are very pleased to be partnering with Uniscience do Brasil to bring Covaris Adaptive Focused Acoustic™ technology to LifeScience,drug discovery and drug development researchers in Brazil,” said Jim Laugharn, Covaris Founder and CEO. “Uniscience has a strong reputation as a market leader in the region and we are looking forward to a very positive business relationship.”
“Covaris is a leader in the area of sample preparation for drug discovery. Covaris and Uniscience complement each other and will build a strong business franchise in Brazil,” said Sergio Joelsons, Uniscience CEO and President.
About Uniscience do Brasil
Based on a pioneering initiative, Uniscience do Brasil (www.uniscience.com) began its activities 29 years ago, aiming to combine technological expertise with development potential. Uniscience partners to integrate intelligent solutions in equipment, reagents, and accessories for the areas of Biotechnology, Diagnostic, and Molecular Biology. Unscience do Brasil’s mission is to act as a partner to our customers by providing reagents, equipment, and supplies high-quality research molecular biology. Our vision is to be recognized as the biotechnology market leader in Brazil with the most complete and reliable product line.
Covaris, Inc. (www.covarisinc.com) provides advanced sample preparation systems for life and analytical science. Covaris sample prep technologies support a wide variety of applications including Next-Generation Sequencing, ChIP, proteomics, formulations, and compound management. Our patented Adaptive Focused Acoustic™ (AFA™) employs highly controlled bursts of focused high-frequency acoustic energy to efficiently and reproducibly process samples in a temperature-controlled and non-contact environment. AFA is the industry standard for DNA shearing, and is used by major genome centers and academic institutions worldwide. It brings unsurpassed speed and efficiency to biological and chemical sample preparation. The AFA process, which is based on shock wave physics, delivers controlled, precise, and accurate acoustic energy to biological and chemical samples.
For additional information, please contact:
14 Gill St Unit H.
Woburn, Massachusetts, USA 01801
001 781 932 3959 ext 206
Covaris provides tools and technologies to improve pre-analytical sample preparation, enable novel drug formulations, and manage compounds in the drug discovery process.